Log In
Print
BCIQ
Print
Print this Print this
 

Subcutaneous rituximab (MabThera SC, Subcutaneous MabThera)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSubcutaneous formulation of rituximab, a chimeric mAb against CD20 antigen
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentApproved
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsFront-line treatment of follicular non-Hodgkin's lymphoma (NHL); Treat follicular lymphoma
Regulatory Designation

EU - Standard Review (Front-line treatment of follicular non-Hodgkin's lymphoma (NHL))

Partner

Chugai Pharmaceutical Co. Ltd.; Genentech Inc.; Halozyme Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today